Incentivizing treatment for opioid and stimulant use disorders in primary care
Contingency Management as a Treatment for Opioid Use Disorder and Stimulant Use Disorder in a Primary Care Setting
NA · University of Minnesota · NCT05288751
This study is testing a program that gives patients money for attending appointments and staying off drugs to see if it helps them stick with their treatment for opioid and stimulant use disorders.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 42 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Minnesota (other) |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT05288751 on ClinicalTrials.gov |
What this trial studies
This study implements a contingency management (CM) program aimed at patients with opioid use disorder, with or without stimulant use disorder, who are starting outpatient addiction medicine services. Participants will receive monetary incentives for attending appointments and for abstaining from substance use, as measured by urine toxicology screens. The goal is to enhance patient engagement and retention in treatment programs within a primary care setting. Data collected will help improve treatment outcomes for individuals receiving medications for opioid use disorder.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of opioid use disorder and/or stimulant use disorder who have recently started medications for opioid use disorder.
Not a fit: Patients with cognitive impairments or those prescribed amphetamines may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment adherence and outcomes for patients with opioid and stimulant use disorders.
How similar studies have performed: Previous studies have shown that contingency management can be effective in treating substance use disorders, indicating potential success for this approach in primary care settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years of age * Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder * Recently initiated medications for opioid use disorder (MOUDs) at Broadway Family Medicine (BFM), within 2 weeks of recruitment * Have an active prescription for buprenorphine-naloxone (Suboxone) Exclusion Criteria: * Prescription for an amphetamine would exclude patients from the abstinence-based CM, but they could participate in the attendance-only CM. * Dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Robert Levy, MD — University of Minnesota
- Study coordinator: Mary Lonergan-Cullum, PhD
- Email: loner026@umn.edu
- Phone: 612-302-8263
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Opioid Use Disorder, Stimulant Use Disorder, opioid use disorder, stimulant use disorder, contingency management, primary care, addiction medicine, buprenorphine